Infinity Pharmaceuticals | INFI - Operating Expenses


Infinity Pharmaceuticals reported $10.7M in Operating Expenses for its fiscal quarter ending in June of 2023.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alterity Therapeutics Limited AUD 7.78M 3M Jun/2023
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.78M 90K Sep/2025
CSL USD 5.7B 2.82B Dec/2025
Eisai JPY 199.9B 16.22B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Grifols EUR 1.77B 22.04M Sep/2025
Incyte USD 1.12B 3.53B Dec/2025
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025